CONTINUUS Pharmaceuticals is leveraging a novel state-of-the-art pharmaceutical manufacturing platform called Integrated Continuous Manufacturing (ICM), initially developed through a Novartis-MIT research collaboration.  ICM represents the most advanced method for producing small-molecule drugs and enables the entire manufacturing process, from starting materials to the final product, to be placed in a single seamless production line. This is a fundamentally different from batch manufacturing, and offers considerable advantages in cost-efficiency, lead time, production flexibility, quality assurance, and environmental impact. Learn more about CONTINUUS and ICM.